Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06751992 · ClinicalTrials.gov registry record · Phase 4

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

A Phase 4 study of Kidney Transplant Recipients and Old Age, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 4
Development phase
92
Enrollment target
1
Study location

NCT06751992: Recruiting Phase 4 study of Kidney Transplant Recipients and Old Age, sponsored by Massachusetts General Hospital.

NCT06751992 is a Phase 4 study of Kidney Transplant Recipients and Old Age that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 92 participants, above the 55-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06751992, a Phase 4 study of Kidney Transplant Recipients and Old Age, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 4
Development phase
92 participants
Enrollment target
1
Study location

Study Summary

The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).

Primary Outcome

Neurocognitive functions will be assessed across multiple cognitive domains using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3. The NIHTB-CB version 3 encompasses seven tests to assess attention, executive function, language, memory, and processing speed. The total cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores \[SS; mean of 100, standard deviation (SD) of 15\] adjusting the age of the subject. The investigators will

Conditions Studied

Kidney Transplant Recipients Old Age

Interventions

  • DRUG Conversion to extended-release tacrolimus
  • DRUG Maintenance of immediate-release tacrolimus

Study Locations (1)

Massachusetts

  • MGH Kidney Transplant Clinic - Boston

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2026-03-17
Est. Completion 2027-10-01
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

What NCT06751992 shows while recruiting

NCT06751992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, above the 55-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target (67% higher).

The record links to 2 conditions, with Kidney Transplant Recipients appearing as the primary indexed condition, and to 2 interventions - of which Conversion to extended-release tacrolimus is the first listed.

NCT06751992 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06751992 about?

NCT06751992 is a clinical study titled "Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients". The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).

What is the current status of trial NCT06751992?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2026-03-17. Estimated completion is 2027-10-01.

What conditions does trial NCT06751992 study?

This clinical trial studies the following conditions: Kidney Transplant Recipients, Old Age.

What interventions are being tested in trial NCT06751992?

The interventions under investigation include: Conversion to extended-release tacrolimus (DRUG), Maintenance of immediate-release tacrolimus (DRUG).

Who is sponsoring clinical trial NCT06751992?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06751992 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Transplant Recipients

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03184545 · 92 participants · Phase 3

    Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

  • NCT04172532 · 92 participants · Phase 1

    Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  • NCT04508088 · 92 participants

    Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

  • NCT04840602 · 92 participants · Phase 2

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06751992

Source: ClinicalTrials.gov NCT06751992, the US trial registry maintained by the National Library of Medicine. NCT06751992 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.